You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國抗體-B(03681.HK)中期虧損擴大至8084萬元
格隆匯 08-24 19:56

格隆匯8月24日丨中國抗體-B(03681.HK)公佈,截至2020年6月30日止6個月,公司收益1865.9萬元人民幣,上年同期收益為21.7萬元;公司擁有人應占虧損8084萬元,上年同期虧損4634.6萬元;每股虧損0.08元。

虧損擴大主要由於行政開支增加約人民幣3800萬元(主要因確認根據公司的受限制股份單位計劃授出受限制股份單位的非現金以股份為基礎付款而產生);研究與開發成本增加約人民幣1500萬元(與集團的SM03、SN1011及SM17的臨牀試驗進展一致);而被其他收入及收益增加約人民幣1840萬元(主要因銀行利息收入及計入損益的金融資產公平值變動而產生)抵銷。

截至2020年及2019年6月30日止6個月,公司產生研發成本分別約人民幣4780萬元及人民幣3280萬元。研發成本增加乃主要由於有關SN1011的I期臨牀試驗的實驗室耗材及試驗成本增加約人民幣1380萬元及因擴充業務而使僱傭成本增加約人民幣220萬元所致。

此外,公司的旗艦產品SM03是潛在的全球同類靶點中首個治療類風濕關節炎的單抗藥物,對其他免疫性疾病亦具有潛在療效,預期於2021年年底前商品化。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account